Aeglea Biotherapeutics

Aeglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes which have been engineered to have optimized catalytic and biopharmaceutic properties. The metabolic basis of tumor amino acid dependence is fundamentally different from the nutritional needs of normal tissues, creating a vulnerability to selective killing of tumor cells. Aeglea’s first two programs utilize enzymes that degrade either the amino acid L-methionine (Met) or L-arginine (Arg) for use as therapy in oncology. The Company's therapeutic strategy takes advantage of decades of clinical validation to leverage the genetic and epigenetic basis of tumor AA auxotrophy to identify patients likely to benefit from these molecules.
Company Growth (employees)
Austin, US
Size (employees)
38 (est)+27%
Aeglea Biotherapeutics was founded in 2013 and is headquartered in Austin, US

Aeglea Biotherapeutics Office Locations

Aeglea Biotherapeutics has an office in Austin
Austin, US (HQ)
250 Barton Oaks Plaza One 901 S MoPac Expy
Show all (1)

Aeglea Biotherapeutics Financials and Metrics

Aeglea Biotherapeutics Financials


Net income (Q2, 2017)

(6.6 m)

EBIT (Q2, 2017)

(6.7 m)

Market capitalization (16-Feb-2018)

99.8 m

Cash (30-Jun-2017)

26.9 m
Aeglea Biotherapeutics's current market capitalization is $99.8 m.
USDFY, 2016

R&D expense

18.1 m

General and administrative expense

8.4 m

Operating expense total

26.5 m


(21.9 m)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

3.6 m4.4 m5.4 m4.9 m5.8 m

General and administrative expense

1.8 m2.4 m2.1 m2.4 m2.4 m

Operating expense total

5.4 m6.9 m7.5 m7.3 m8.2 m


(4.6 m)(5.5 m)(6.3 m)(6.3 m)(6.7 m)
USDFY, 2016


47.7 m

Accounts Receivable

164.2 m


1.7 m

Current Assets

66.4 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


24 m70.6 m49.5 m16.8 m26.9 m

Current Assets

35.2 m76.9 m71.7 m60.3 m66.2 m


321 k377 k342 k822 k802 k

Total Assets

35.5 m77.3 m72.1 m61.3 m67.1 m
USDFY, 2016

Net Income

(21.7 m)

Depreciation and Amortization

132 k

Accounts Receivable

(43.6 k)


(96.1 k)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(4.5 m)(5.4 m)(6.2 m)(6.2 m)

Accounts Payable

509 k348 k523 k267 k
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

Aeglea Biotherapeutics Operating Metrics

FY, 2016

Nonclinical Development


Phase 1/2


Phase I Trials


Phase Approved

Show all operating metrics

Aeglea Biotherapeutics Market Value History

Aeglea Biotherapeutics's Web-traffic and Trends

Aeglea Biotherapeutics Company Life and Culture

You may also be interested in